Humulin N, also known as insulin isophane suspension, is a type of intermediate-acting insulin used to manage blood sugar levels in people with diabetes [1]. The price of Humulin N can vary significantly depending on factors such as dosage, quantity, pharmacy, and insurance coverage [2].
How Much Does Humulin N Cost Without Insurance?
Without insurance, a 10 mL vial of Humulin N can range from approximately $25 to $50 or more. A box of five 3 mL pens (Humulin N KwikPen) can cost between $100 and $200 or more [2]. These figures represent general estimates, and actual costs at individual pharmacies may differ.
Can I Get Humulin N Cheaper with a Coupon?
Discount cards and coupons can help lower the out-of-pocket cost of Humulin N. Several pharmaceutical discount programs offer savings on insulin products. For example, Eli Lilly and Company, the manufacturer of Humulin N, may offer savings cards or patient assistance programs that can reduce the price for eligible individuals [2]. Websites like GoodRx and SingleCare also list coupons and discounts available for Humulin N at various pharmacies [2].
What is the Price of Humulin N with Insurance?
With health insurance, the cost of Humulin N is typically lower, often falling within a copay range set by the insurance plan. This copay can be anywhere from a few dollars to $50 or more per prescription, depending on the specific insurance formulary and whether the drug is preferred [2]. Patients are advised to check with their insurance provider for precise cost details.
How Does Humulin N Pricing Compare to Other Insulins?
Humulin N is generally considered a more affordable insulin option compared to newer, rapid-acting insulins or analog insulins. However, prices can fluctuate based on market dynamics and the availability of generic alternatives [3]. Information on insulin pricing and accessibility can be found on resources like DrugPatentWatch.com [4].
When Does the Patent for Humulin N Expire?
Humulin N is an older insulin product, and its patents have long since expired, allowing for the availability of biosimilar or generic versions of insulin isophane suspension. The original patents for recombinant DNA technology used to produce insulin expired decades ago [4]. This patent expiry has contributed to its availability as a more cost-effective option.